Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 236.8% in the first quarter, HoldingsChannel.com reports. The fund owned 30,827 shares of the company’s stock after purchasing an additional 21,673 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Protagonist Therapeutics were worth $892,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in PTGX. China Universal Asset Management Co. Ltd. raised its holdings in shares of Protagonist Therapeutics by 353.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock worth $153,000 after acquiring an additional 5,202 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Protagonist Therapeutics by 11.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,338 shares of the company’s stock worth $237,000 after acquiring an additional 1,093 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 13.4% in the third quarter. Profund Advisors LLC now owns 58,716 shares of the company’s stock worth $979,000 after acquiring an additional 6,933 shares during the last quarter. Federated Hermes Inc. increased its stake in Protagonist Therapeutics by 102.6% in the third quarter. Federated Hermes Inc. now owns 60,234 shares of the company’s stock valued at $1,005,000 after purchasing an additional 30,507 shares during the last quarter. Finally, Birchview Capital LP increased its stake in Protagonist Therapeutics by 26.3% in the fourth quarter. Birchview Capital LP now owns 48,000 shares of the company’s stock valued at $1,101,000 after purchasing an additional 10,000 shares during the last quarter. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Trading Down 0.8 %

PTGX stock opened at $32.01 on Tuesday. The stock has a 50-day moving average price of $29.44 and a two-hundred day moving average price of $27.38. Protagonist Therapeutics, Inc. has a 12-month low of $13.72 and a 12-month high of $35.96. The company has a market cap of $1.88 billion, a PE ratio of 13.12 and a beta of 2.12.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.75. The firm had revenue of $254.95 million for the quarter, compared to analysts’ expectations of $300.00 million. Equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.29 EPS for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $28.31, for a total value of $707,750.00. Following the completion of the sale, the chief executive officer now owns 549,590 shares of the company’s stock, valued at $15,558,892.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $28.31, for a total value of $707,750.00. Following the completion of the sale, the chief executive officer now owns 549,590 shares of the company’s stock, valued at $15,558,892.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Asif Ali sold 1,234 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $25.11, for a total value of $30,985.74. Following the completion of the sale, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The disclosure for this sale can be found here. Insiders sold 69,234 shares of company stock valued at $2,250,386 over the last quarter. Company insiders own 5.40% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on PTGX shares. StockNews.com upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a research note on Friday, June 14th. JMP Securities reiterated a “market outperform” rating and issued a $45.00 target price on shares of Protagonist Therapeutics in a research note on Monday, June 17th. Finally, JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $38.00.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.